Ginkgo Bioworks Holdings (DNA) Accumulated Expenses (2020 - 2026)

Ginkgo Bioworks Holdings' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $48.4 million for Q1 2026.

• Quarterly Accumulated Expenses fell 31.62% year-over-year to $48.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.4 million (down 31.62% YoY) and the FY2025 annual result came in at $66.5 million, up 1.64% from the prior year.
• Accumulated Expenses was $48.4 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $66.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $122.6 million in Q1 2023 and bottomed at $48.4 million in Q1 2026.
• A 5-year average of $87.9 million and a median of $79.3 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 57.69% — and 2025, when it tumbled 51.13%.
• Ginkgo Bioworks Holdings' Accumulated Expenses stood at $114.7 million in 2022, then decreased by 4.05% to $110.1 million in 2023, then slumped by 40.58% to $65.4 million in 2024, then grew by 1.64% to $66.5 million in 2025, then declined by 27.21% to $48.4 million in 2026.
• Business Quant data shows DNA's Accumulated Expenses at $48.4 million in Q1 2026, $66.5 million in Q4 2025, and $79.3 million in Q3 2025.